Autori: Goel Shom
| Naslov | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2 (Article) |
| Autori | Goel Shom Tan Antoinette R Rugo Hope S Aftimos Philippe Andric Zoran G Beelen Andrew Paul Zhang Jingshan Yi John S Malik Rajesh K O'Shaughnessy Joyce |
| Info | FUTURE ONCOLOGY, (2022), vol. 18 br. 33, str. 3701-3711 |
| Projekat | G1 Therapeutics; Eli Lilly; Merck; Pfizer; AstraZeneca; Ayala; Boehringer Ingelheim; Daiichi; Gilead; Lilly; Macrogenics; Novartis; OBI; Odonate; Polyphor; Roche; Seattle Genetics; Sermonix |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). (Meeting Abstract) |
| Autori | Goel Shom O'Shaughnessy Joyce Tan Antoinette R Milev-Krastev Boris Rugo Hope S Aftimos Philippe Georges Yardley Denise A Andric Zoran G Wolfgang Curt Douglas Sorrentino Jessica Tao Wenli Beelen Andrew Paul Malik Rajesh K Jain Sarika |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2021), vol. 39 br. 15, Suppl. S, str. - |
| Projekat | G1 Therapeutics, Inc |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
